The effect of age, sex, and eastern cooperative oncology group performance status on the efficacy and safety of immune checkpoint inhibitors in patients with hepatocellular carcinoma: a systematic review and meta-analysis

CONCLUSION: ICI therapy in HCC should not be restricted strictly to certain patients in age or sex categories, while HCC patients with higher ECOG PS may require closer medication or follow-up strategy during ICI therapy.PROSPERO REGISTRATION: CRD42024518407.PMID:38623811 | DOI:10.1080/14737140.2024.2341723

Source: Expert Review of Anticancer Therapy - April 16, 2024 Category: Cancer & Oncology Authors: Cheng-Long Han Bao-Wen Tian Lun-Jie Yan Zi-Niu Ding Hui Liu Guo-Qiang Pan Xiao Zhang Xin-Chen Mao Si-Yu Tan Rui-Zhe Li Dong-Xu Wang Zhao-Ru Dong Yu-Chuan Yan Tao Li Source Type: research